Article | September 3, 2021

Designing Agile Manufacturing With An Integrated Drug Substance/Drug Product Ecosystem

Source: Cytiva
Cytiva

New therapies are emerging across the pharmaceutical landscape, due to a convergence of scientific discoveries and innovative technologies. While these therapies bring new hope to patient care, they also add challenges to a complex path to market.

Unpredictable timelines, high drug attrition rates, and decision-making that is in constant instability are all factors that threaten the ability to bring a therapy to market. Flexibility in development and manufacturing is a key factor in establishing operations that can respond to these variables and changing market conditions while also increasing efficiency.

Small and emerging companies that want to accelerate their biomanufacturing operations and protect their resources must find technologies and solutions to complete their workflow safely and efficiently – from idea to injection.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma